People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Chronic pain is a worldwide epidemic that disproportionately affects women. These surgeons have found innovative solutions - ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

At least one person is dead Thursday morning after a fatal two-vehicle crash in north St. Louis involving a city garbage ...

"Anti-vaccine rhetoric is a threat to global health," said biomedical scientist Andrea C. Love, PhD, emphasizing how ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

The pros and cons of weight loss drugs. HARTFORD, Conn. (WTNH) — The biggest employer in Connecticut is the state. While other states ...